Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 39, 2008, Pages 15040-15045

  Eikesdal, Hans Petter ^a   Sugimoto, Hikaru ^a   Birrane, Gabriel ^a   Maeshima, Yohei ^a   Cooke, Vesselina G ^a   Kieran, Mark ^b   Kalluri, Raghu ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

V 3 integrin; Angiogenesis; Bevacizumab; Tumstatin peptide

Indexed keywords

BEVACIZUMAB; TUMSTATIN; VITRONECTIN RECEPTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ASPARTIC ACID; AUTOANTIGEN; COLLAGEN TYPE 4; LEUCINE; MONOCLONAL ANTIBODY; TYPE IV COLLAGEN ALPHA3 CHAIN; VALINE;

AMINO ACID ANALYSIS; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; AMINO ACID SUBSTITUTION; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; GENETICS; KIDNEY TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PROTEIN CONFORMATION; VASCULARIZATION;

AMINO ACID SUBSTITUTION; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTIC ACID; AUTOANTIGENS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE IV; ENDOTHELIAL CELLS; HUMANS; INTEGRIN ALPHAVBETA3; KIDNEY NEOPLASMS; LEUCINE; MICE; MICE, INBRED C57BL; MUTAGENESIS, SITE-DIRECTED; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN CONFORMATION; VALINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54449094358     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0807055105     Document Type: Article

References (28)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70.
2. Maeshima Y, et al. (2000) Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 275:21340-21348.
3. Maeshima Y, et al. (2001) Extracellular matrix-derived peptide binds to alpha (v) beta(3) integrin and inhibits angiogenesis. J Biol Chem 276: 31959-31968.
4. Humphries JD, Byron A, Humphries MJ (2006) Integrin ligands at a glance. J Cell Sci 119:3901-3903.
5. Ginsberg MH, Partridge A, Shattil SJ (2005) Integrin regulation. Curr Opin Cell Biol 17:509-516.
6. Hamano Y, et al. (2003) Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 3:589-601.
7. Maeshima Y, Colorado PC, Kalluri R (2000) Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 275:23745-23750.
8. Maeshima Y, et al. (2002) Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295:140-143.
9. Siebold B, Deutzmann R, Kuhn K (1988) The arrangement of intra- and intermolecular disulfide bonds in the carboxyterminal, non-collagenous aggregation and cross-linking domain of basement-membrane type IV collagen. Eur J Biochem 176:617-624.
10. Petitclerc E, et al. (2000) New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 275:8051-8061.
11. Xiong JP, et al. (2002) Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 296:151-155.
12. Than ME, et al. (2002) The 1.9-A crystal structure of the noncollagenous (NC1) domain of human placenta collagen IV shows stabilization via a novel type of covalent Met-Lys cross-link. Proc Natl Acad Sci USA 99:6607-6612.
13. Nicholls A, Sharp KA, Honig B (1991) Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 11:281-296.
14. Fenn TD, Ringe D, Petsko GA (2003) Povscript+: A program for model and data visualization using persistence of vision ray-tracing. J Appl Crystallogr 36:944-947.
15. Sund M, Zeisberg M, Kalluri R (2005) Endogenous stimulators and inhibitors of angiogenesis in gastrointestinal cancers: Basic science to clinical application. Gastroenterology 129:2076-2091.
16. Stommel JM, et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-290.
17. Relf M, et al. (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969.
18. Miller KD, Sweeney CJ, Sledge GWJ (2003) The Snark is a Boojum: The continuing problem of drug resistance in the antiangiogenic era. Ann Oncol 14:20-28.
19. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410.
20. Huang J, et al. (2004) Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2:36-42.
21. Yang JC, et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434.
22. Escudier B, et al. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma:Arandomised, double-blind phase III trial. Lancet 370:2103-2111.
23. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727-739.
24. Batchelor TT, et al. (2007) AZD2171, a Pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95.
25. Iughetti P, et al. (2001) A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 61:7375-7378.
26. Lourenco GJ, et al. (2006) A high risk of occurrence of sporadic breast cancer in individuals with the 104NN polymorphism of the COL18A1 gene. Br Cancer Res Treat 100:335-338.
27. Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779-815.
28. Tovchigrechko A, Vakser IA (2005) Development and testing of an automated approach to protein docking. Proteins 60:296-301.